Skip to search formSkip to main contentSkip to account menu

dabigatran etexilate

Known as: Etexilate, Dabigatran, Ethyl 3-(((2-(((4- ((((hexyloxy)carbonyl)amino)iminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)(pyridin-2- yl)amino)propanoate, Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

Pradaxa

Broader (1)

dabigatran
dabigatran etexilate 150 MG Oral Capsule [Pradaxa]dabigatran etexilate 75 MG Oral Capsuledabigatran etexilate mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
Highly Cited
2014
Highly Cited
2014
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel
Note: The editorial process for this paper was fully handled by Prof Christian Weber, Editor in Chief. 
Highly Cited
2013
Highly Cited
2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
Background— During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY… 
Review
2012
Review
2012
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
Review
2012
Review
2012
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice
Summary Dabigatran etexilate is a new oral anticoagulant recently approved in Europe for the prevention of stroke or systemic… 
Highly Cited
2011
Highly Cited
2011
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
Summary Oral dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in patients with atrial… 
Review
2011
Review
2011
The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
Highly Cited
2008
Highly Cited
2008
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty
Summary Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE… 
Review
2008
Review
2008
Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases
As the only oral anticoagulation option available in the United States, warfarin use remains widespread. However, concerns of… 
Highly Cited
2005
Highly Cited
2005
Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
Dabigatran etexilate is an oral low‐molecular‐weight direct thrombin inhibitor. Following oral administration, dabigatran… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)